On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy

Frontiers in Microbiology

Volumn 6, Issue NOV, 2015, Pages

  Mattila, Sari ^a   Ruotsalainen, Pilvi ^a   Jalasvuori, Matti ^a  

^a UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

Antibiotic resistance; Bacteriophages; ESBL; MRSA; Phage cocktails; Phage therapy

Indexed keywords

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; BACTERIUM ISOLATION; CROSS INFECTION; ENTEROCOCCUS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SALMONELLA;

EID: 84949750068     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01271     Document Type: Article

References (30)

1. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., and Kutter, E. M. (2011). Phage treatment of human infections. Bacteriophage 1, 66-85. doi: 10.4161/bact.1.2.15845
2. Agnihotri, N., Gupta, V., and Joshi, R. M. (2004). Aerobic bacterial isolates from burn wound infections and their antibiograms-a five-year study. Burns 30, 241-243. doi: 10.1016/j.burns.2003.11.010
3. Atanasova, N. S., Roine, E., Oren, A., Bamford, D. H., and Oksanen, H. M. (2012). Global network of specific virus-host interactions in hypersaline environments. Environ. Microbiol. 14, 426-440. doi: 10.1111/j.1462-2920.2011.02603.x
4. Cantas, L., Shah, S. Q., Cavaco, L. M., Manaia, C. M., Walsh, F., Popowska, M., et al. (2013). A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota. Front. Microbiol. 4:96. doi: 10.3389/fmicb.2013.00096
5. CDC (2013). Antibiotic Resistance Threats in the United States, 2013. US Centers for Disease Control and Prevention. U.S Department of Health and Human Services. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
6. CDC/FDA/NIH (2011). A Public Health Action Plan to Combat Antimicrobial Resistance. Atlanta, GA: U.S. Centers for Disease Control and Prevention/U.S. Food and Drug Administration/National Institutes of Health.
7. Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769-783. doi: 10.2217/fmb.13.47
8. Clokie, M. R., Millard, A. D., Letarov, A. V., and Heaphy, S. (2011). Phages in nature. Bacteriophage 1, 31-45. doi: 10.4161/bact.1.1.14942
9. Finch, R. (2011). Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J. Antimicrob. Chemother. 66, 1945-1947. doi: 10.1093/jac/dkr259
10. Flores, C. O., Meyer, J. R., Valverde, S., Farr, L., and Weitz, J. S. (2011). Statistical structure of host-phage interactions. Proc. Natl. Acad. Sci. U.S.A. 108, E288-E297. doi: 10.1073/pnas.1101595108
11. Gill, J. J., and Hyman, P. (2010). Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 11, 2-14. doi: 10.2174/138920110790725311
12. Hendrix, R. W., Smith, M. C. M., Burns, R. N., Ford, M. E., and Hatfull, G. F. (1999). Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage. Proc. Natl. Acad. Sci. U.S.A. 96, 2192-2197. doi: 10.1073/pnas.96.5.2192
13. Hyman, P., and Abedon, S. T. (2010). Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 70, 217-248. doi: 10.1016/S0065-2164(10)70007-1
14. Keen, E. C. (2012). Phage therapy: concept to cure. Front. Microbiol. 3:238. doi: 10.3389/fmicb.2012.00238
15. Kelly, D., McAuliffe, O., Ross, R. P., O'Mahony, J., and Coffey, A. (2011). Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs 2, 31-37. doi: 10.4161/bbug.2.1.13657
16. Labrie, S. J., Samson, J. E., and Moineau, S. (2010). Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8, 317-327. doi: 10.1038/nrmicro2315
17. Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459. doi: 10.1038/nature14098
18. Lobocka, M., Hejnowicz, M. S., Gkagala, U., Weber-Dkabrowska, B., Wkegrzyn, G., and Dadlez, M. (2014). "The first step to bacteriophage therapy-how to choose the correct phage". in Phage Therapy: Current Research and Applications, eds J. Borysowski, R. Mikedzybrodzki, and A. Górski (Norfolk: Caister Academic Press).
19. Loc-Carrillo, C., and Abedon, S. T. (2011). Pros and cons of phage therapy. Bacteriophage 1, 111-114. doi: 10.4161/bact.1.2.14590
20. Loc-Carrillo, C., Wu, S., and Beck, J. P. (2012). "Phage therapy of wounds and related purulent infections". in Bacteriophages in Health and Disease, eds P. Hyman and S. T. Abedon (Wallingford: CABI Press), 185-202.
21. Lu, T. K., and Koeris, M. S. (2011). The next generation of bacteriophage therapy. Curr. Opin. Microbiol. 14, 524-531. doi: 10.1016/j.mib.2011.07.028
22. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:e4944. doi: 10.1371/journal.pone.0004944
23. Örmälä, A.-M., and Jalasvuori, M. (2013). Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 3, e24219. doi: 10.4161/bact.24219
24. Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., et al. (2011). The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm. Res. 28, 934-937. doi: 10.1007/s11095-010-0313-5
25. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
26. Skurnik, M., Pajunen, M., and Kiljunen, S. (2007). Biotechnological challenges of phage therapy. Biotechnol. Lett. 29, 995-1003. doi: 10.1007/s10529-007-9346-1
27. Sommer, M. O., and Dantas, G. (2011). Antibiotics and the resistant microbiome. Curr. Opin. Microbiol. 14, 556-563. doi: 10.1016/j.mib.2011.07.005
28. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
29. World Health Organization [WHO] (2014). Antimicrobial Resistance: Global Report on Surveillance. Available at: http://www.who.int/drugresistance/documents/surveillancereport/en/[accessed September 12, 2015].
30. Zhukov-Verezhnikov, N. N., Peremitina, L. D., Berillo, E. A., Komissarov, V. P., Bardymov, V. M., Khvoles, A. G., et al. (1978). A study of the therapeutic effect of bacteriophage agents in a complex treatment of suppurative surgical diseases. Sov. Med. 12, 64-66.